

SARS-CoV-2

COVID-19 Delta Variant Pseudovirus Neutralizing Antibody Assay (Luciferase)


Catalog # DE0007

Size 1 Kit

Applications


Neutralization

RBD-binding IgG responses in mouse sera collected 35 days and 42 days after immunization with 5 ug or 20 ug COVID-19 RBD SAM LNP no adjuvant (ppopV0) and 5 ug or 20 ug COVID-19 RBD SAM plus adjuvant (ppopV1).



Neutralization

SARS-CoV-2 delta variant spike pseudovirus expressing luciferase is treated with humanized monoclonal antibody 7F7, and then added into 293T-ACE cells.



Specification

Product Description

COVID-19 Delta Variant Pseudovirus Neutralizing Antibody Assay (Luciferase) provides a highly sensitive and quantitative measurement of neutralizing antibodies.

Supplied Product

Kit content:

1 kit is sufficient for 100 assays in 24 well plates

1. 293T-hACE2 cell, 2×10^6 cells/vial, FBS with 10% DMSO

2. SARS-CoV-2 Delta Variant Pseudovirus Expressing Luciferase

Materials Required But NOT Supplied

1. SARS-CoV-2 Monoclonal Antibody, Cat# MAB22854-M07, Abnova
2. ZymeFree™ Enzyme Free Cell Dissociation Reagent, Cat# TCL028-100ML, HIMEDIA
3. DMEM culture medium containing 10% FBS (complete medium)
4. Luciferase Assay System, Cat# E1500, Promega
 - a. Luciferase Assay Substrate (lyophilized)
 - b. Luciferase Assay Buffer
 - c. Luciferase Cell Culture Lysis Reagent, 5X
5. TC-Treated 24 Well Plates, Cat# 3524, Corning
6. OptiPlate™-96, Cat# 6005290, PerkinElmer

Variant

B.1.617.2

Suitable Sample

1. Immunized Serum
2. Infected Serum
3. Neutralizing Antibodies
4. Peptide Inhibitors or Proteins
5. Compounds Targeting Spike Induced Cell Fusion

Sample Volume

10-50 uL (please check sample source)

Detection Method

Luciferase Activity

Technology
[Pseudovirus](#)
Regulatory Status

For research use only (RUO)

Storage Instruction

293T-hACE2 cell Store at liquid nitrogen.
 Pseudovirus Store at -80°C.
 Aliquot to avoid repeated freezing and thawing.

Applications

- Neutralization

RBD-binding IgG responses in mouse sera collected 35 days and 42 days after immunization with 5 ug or 20 ug COVID-19 RBD SAM LNP no adjuvant (ppopV0) and 5 ug or 20 ug COVID-19 RBD SAM plus adjuvant (ppopV1).

- Neutralization

SARS-CoV-2 delta variant spike pseudovirus expressing luciferase is treated with humanized monoclonal antibody 7F7, and then added into 293T-ACE cells.